FDA data Registry peer set 2 peers FDA shortage listed

Alternatives to guanfacine

FDA shortage status is active for guanfacine; 2 same-class SPL records are listed below for registry comparison only.

Brand: Intuniv, Tenex

Central Alpha-2 Agonist Prescription 2 alternatives found

guanfacine class peers while FDA lists an active shortage

guanfacine (Intuniv, Tenex) is on an FDA shortage listing while 2 other Central Alpha-2 Agonist SPL records remain in this registry peer set (class inventory 3). Labeled indication field for guanfacine: Guanfacine extended-release tablets are used to treat Attention Deficit Hyperactivity Disorder (ADHD).

Top FAERS reaction fields for guanfacine total 3,009 reports across 10 reactions, set beside clonidine, methyldopa. Counts are exposure-weighted submissions, not per-patient risk.

About guanfacine

Guanfacine extended-release tablets can help treat ADHD. It can be used alone or with stimulant medicines.

Used for: Guanfacine extended-release tablets are used to treat Attention Deficit Hyperactivity Disorder (ADHD). It can be used by itself or with other stimulant medicines to help manage ADHD symptoms. This medicine works by affecting certain receptors in the brain.

2 Central Alpha-2 Agonist peers (wide set)

Compare guanfacine vs clonidine side-by-side →

guanfacine vs clonidine & methyldopa · FAERS reaction fields

FAERS top-reaction field "Fatigue" shows the widest count spread between guanfacine and clonidine, methyldopa in this extract (2,596-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect guanfacine clonidinemethyldopa
Somnolence 455 - -
Aggression 376 - -
Fatigue 329 2,925 -
Hypotension 289 1,542 -
Dizziness 270 1,876 -
Headache 268 2,798 123
Insomnia 264 - -
Suicidal Ideation 259 - -

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

guanfacine shortage vs Central Alpha-2 Agonist peer index

Shortage status

FDA shortage listing is active for guanfacine (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.

Frequently Asked Questions

Does FDA list a shortage for guanfacine while peers remain indexed?
Yes - guanfacine matched an active FDA shortage listing (To Be Discontinued) while 2 other Central Alpha-2 Agonist SPL records remain in this peer index for field comparison only.

Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full guanfacine profile →

Field note for guanfacine: see also the generic vs brand label guide when reading Intuniv SPL strings.